Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

LIFECORE BIOMEDICAL, INC.

Filed: Jun 4, 2026CIK: 0001005286
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Lifecore Biomedical stockholders approved the 2026 Stock Incentive Plan on June 4, 2026, authorizing up to 2.5 million shares for employee compensation. The plan becomes effective October 16, 2026, replacing the expiring 2019 plan and reflects the company's strategic shift to align employee incentives with shareholder value.

Key Takeaways

2026 Stock Incentive Plan approved by stockholders with authorization for up to 2,500,000 shares of Common Stock

Plan becomes effective October 16, 2026, and replaces the 2019 Stock Incentive Plan upon its expiration

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 4, 2026
Item5.02
CategoryExecutive Change
CIK0001005286
Accession #lfcr-20260604
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
material agreement

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings